Table 3.

Clinical data of the patients who got a probable or possible breakthrough infection

Pt	Demographic and clinical data	Initial posaconazole trough (mg/L)	Subsequent posaconazole troughs (mg/L)	IFI treatment	Chemotherapy/antimicrobial therapy	Diagnosis of IFI
1	59‐year‐old woman with AML and had received a SCT	2.37 mg/L	NI	Amphotericin B with caspofungin	Cytarabine (1000 mg/m2)/daunorubicin (60 mg/m2), prednisolone, piperacillin/tazobactam	HRCT: positive changes in the scan, galactomannan antigen serum index: 0.56, galactomannan antigene BAL index 0.35
2	46‐year‐old man with AML	1.26 mg/L	2.6 mg/L, 3.2 mg/L	Amphotericin B followed by caspofungin	Cytarabine (1000 mg/m2)/daunorubicin (60 mg/m2), colistin, piperacillin‐tazobactam, vancomycin	HRCT: positive masses in liver, galactomannan antigene serum index: 0.10
3	59‐year‐old man with systemic mastocytosis and had received a SCT	1.2 mg/L	2.4 mg/L, 1.8 mg/L	Amphotericin B with caspofungin	Ruxolitinib, cyclosporine, prednisolone, azithromycin	Galactomannan antigene BAL index 4.90

Abbreviation: NI, no information.